Tao Zhang

Tao Zhang

Auto-generated profile, based on publicly available information

Tao Zhang

Shanghai Institute of Materia Medica

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
LZLin-Lin Zhou
Lin-Lin Zhou
TZTao Zhang
Tao Zhang
YXYun Xue
Yun Xue
CYChuan Yue
Chuan Yue
YPYihui Pan
Yihui Pan
CYCai-Guang Yang
Cai-Guang Yang
Chemo-activation of mitochondrial ClpP exhibits promising anticancer properties. However, we are currently unaware of any studies using selective and potent ClpP activators in lung squamous cell carcinoma. In this work, we report on such an activator, ZK53, which exhibits therapeutic effects on lung squamous cell carcinoma in vivo. The crystal structure of ZK53/ClpP complex reveals a π-π stacking effect that is essential for ligand binding selectively to the mitochondrial ClpP. ZK53 features on a simple scaffold, which is distinct from the activators with rigid scaffolds, such as acyldepsipeptides and imipridones. ZK53 treatment causes a decrease of the electron transport chain in a ClpP-dependent manner, which results in declined oxidative phosphorylation and ATP production in lung tumor cells. Mechanistically, ZK53 inhibits the adenoviral early region 2 binding factor targets and activates the ataxia-telangiectasia mutated-mediated DNA damage response, eventually triggering cell cycle arrest. Lastly, ZK53 exhibits therapeutic effects on lung squamous cell carcinoma cells in xenograft and autochthonous mouse models.

14 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
BWBingyan Wei
Bingyan Wei
TZTao Zhang
Tao Zhang
PWPengyu Wang
Pengyu Wang
YPYihui Pan
Yihui Pan
JLJiahui Li
Jiahui Li
CYCai-Guang Yang
Cai-Guang Yang
The emergence of methicillin-resistant Staphylococcus aureus isolates highlights the urgent need to develop more antibiotics. ClpP is a highly conserved protease regulated by ATPases in bacteria and in mitochondria. Aberrant activation of bacterial ClpP is an alternative method of discovering antibiotics, while it remains difficult to develop selective Staphylococcus aureus ClpP activators that can avoid disturbing Homo sapiens ClpP functions. Here, we use a structure-based design to identify (R)- and (S)-ZG197 as highly selective Staphylococcus aureus ClpP activators. The key structural elements in Homo sapiens ClpP, particularly W146 and its joint action with the C-terminal motif, significantly contribute to the discrimination of the activators. Our selective activators display wide antibiotic properties towards an array of multidrug-resistant staphylococcal strains in vitro, and demonstrate promising antibiotic efficacy in zebrafish and murine skin infection models. Our findings indicate that the species-specific activators of Staphylococcus aureus ClpP are exciting therapeutic agents to treat staphylococcal infections.

19 February 2024 in RSC Chemical Biology
Verified
Journal Article
Open access
PDF file
GLGan-Qiang Lai
Gan-Qiang Lai
YLYali Li
Yali Li
HZHeping Zhu
Heping Zhu
TZTao Zhang
Tao Zhang
JGJing Gao
Jing Gao
CYCai-Guang Yang
Cai-Guang Yang
N 6-Methyladenosine (m6A) is the most prevalent mRNA modification and is required for gene regulation in eukaryotes. ALKBH5, an m6A demethylase, is a promising target, particularly for anticancer drug discovery. However, the development of selective and potent inhibitors of ALKBH5 rather than FTO remains challenging. Herein, we used a targeted covalent inhibition strategy and identified a covalent inhibitor, TD19, which selectively inhibits ALKBH5 compared with FTO demethylase in protein-based and tumor cell-based assays. TD19 irreversibly modifies the residues C100 and C267, preventing ALKBH5 from binding to m6A-containing RNA. Moreover, TD19 displays good anticancer efficacy in acute myeloid leukemia and glioblastoma multiforme cell lines. Thus, the ALKBH5 inhibitor developed in this study, which selectively targets ALKBH5 compared with FTO, can potentially be used as a probe for investigating the biological functions of RNA demethylase and as a lead compound in anticancer research.

1 November 2021 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
XGXiang-Na Guan
Xiang-Na Guan
TZTao Zhang
Tao Zhang
TYTeng Yang
Teng Yang
ZDZe Dong
Ze Dong
SYSong Yang
Song Yang
CYCai-Guang Yang
Cai-Guang Yang
Covalent sortase A inhibitor ML346 prevents Galleria mellonella from Staphylococcus aureus infection by interfering in the transpeptidation activity of sortase A for anchoring surface proteins into staphylococci envelope.

22 September 2023 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
YLYingqiang Liu
Yingqiang Liu
ZZZhengsheng Zhan
Zhengsheng Zhan
ZKZhuang Kang
Zhuang Kang
MLMengyuan Li
Mengyuan Li
YLYongcong Lv
Yongcong Lv
JDJian Ding
Jian Ding
Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults and is poorly controlled. Previous studies have shown that both macrophages and angiogenesis play significant roles in GBM progression, and co-targeting of CSF1R and VEGFR is likely to be an effective strategy for GBM treatment. Therefore, this study developed a novel and selective inhibitor of CSF1R and VEGFR, SYHA1813, possessing potent antitumor activity against GBM. SYHA1813 inhibited VEGFR and CSF1R kinase activities with high potency and selectivity and thus blocked the cell viability of HUVECs and macrophages and exhibited anti-angiogenetic effects both in vitro and in vivo. SYHA1813 also displayed potent in vivo antitumor activity against GBM in immune-competent and immune-deficient mouse models, including temozolomide (TMZ) insensitive tumors. Notably, SYHA1813 could penetrate the blood–brain barrier (BBB) and prolong the survival time of mice bearing intracranial GBM xenografts. Moreover, SYHA1813 treatment resulted in a synergistic antitumor efficacy in combination with the PD-1 antibody. As a clinical proof of concept, SYHA1813 achieved confirmed responses in patients with recurrent GBM in an ongoing first-in-human phase I trial. The data of this study support the rationale for an ongoing phase I clinical study (ChiCTR2100045380).

16 June 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RZRanran Zhang
Ranran Zhang
PWPengyu Wang
Pengyu Wang
BWBingyan Wei
Bingyan Wei
LCLiang Chen
Liang Chen
XSXiaomin Song
Xiaomin Song
CYCai-Guang Yang
Cai-Guang Yang